In a filing, Zevra Therapeutics Inc revealed its Chief Legal & Compliance Thompson Rahsaan unloaded Company’s shares for reported $0.22 million on Jun 26 ’25. In the deal valued at $9.21 per share,24,000 shares were sold. As a result of this transaction, Thompson Rahsaan now holds 42,666 shares worth roughly $0.53 million.
Then, RAHSAAN THOMPSON bought 24,000 shares, generating $223,920 in total proceeds.
Before that, Watton Corey Michael bought 300 shares. Zevra Therapeutics Inc shares valued at $2,352 were divested by the Director at a price of $7.84 per share. As a result of the transaction, Watton Corey Michael now holds 1,800 shares, worth roughly $22554.0.
H.C. Wainwright initiated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on July 02, 2025; the price target was $26. Guggenheim began covering ZVRA with “Buy” recommendation on October 07, 2024. Maxim Group maintained its rating on September 24, 2024. It rated ZVRA as “a Buy”.
Price Performance Review of ZVRA
On Friday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock jump 4.24% to $12.53. Over the last five days, the stock has gained 28.64%. Zevra Therapeutics Inc shares have risen nearly 179.06% since the year began. Nevertheless, the stocks have risen 50.24% over the past one year. While a 52-week high of $12.37 was reached on 07/11/25, a 52-week low of $5.45 was recorded on 04/09/25.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 12.09, which if violated will result in even more drops to 11.66. On the upside, there is a resistance level at 12.76. A further resistance level may holdings at 12.99.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-06-13, dropping by -1.3 million shares to a total of 4.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.01 million shares. There was a decline of -27.55%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 24, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $17 price target.
